Sign in

    Kevin StrangGoldman Sachs Group

    Kevin Strang's questions to Syndax Pharmaceuticals Inc (SNDX) leadership

    Kevin Strang's questions to Syndax Pharmaceuticals Inc (SNDX) leadership • Q2 2025

    Question

    Kevin Strang, on behalf of Corinne Johnson, inquired about the Revuforge treatment timeline, asking how many cycles typically occur before a stem cell transplant and what proportion of patients are ultimately expected to receive post-transplant maintenance therapy.

    Answer

    CEO Michael Metzger explained that patients typically receive Revuforge for two to three cycles before proceeding to transplant. He noted that while about one-third of commercial patients have gone to transplant so far, this rate is expected to increase as the drug is used in earlier lines of therapy. He added that physicians intend to put the vast majority, potentially 70-90%, of eligible patients back on maintenance therapy post-transplant.

    Ask Fintool Equity Research AI